Physician profile
Meagan Cherry
NPI 1871945816
$623.44
in general payments reported to CMS, 2019-2025
16 companies · $20.95 in 2025
The $20.95 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $70.68 · 2022: $197 · 2023: $320 · 2024: $14.75 · 2025: $20.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $355.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $114.32 | 2021-2024 | Evenity, Prolia |
| Abbvie INC. | $72.15 | 2022-2023 | |
| Novo Nordisk INC | $69.30 | 2022-2023 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $67.83 | 2023 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $50.83 | 2022-2023 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $49.08 | 2021-2023 | Farxiga |
| Pfizer INC. | $30.30 | 2023 | |
| Genentech USA, INC. | $29.07 | 2021 | |
| Lilly USA, LLC | $28.52 | 2022-2023 | Mounjaro, Trulicity |
| Astellas Pharma US INC | $22.29 | 2023 | Veozah |
| Abbott Laboratories | $20.95 | 2025 | Freestyle Libre 3 |
| Nevro Corp. | $17.59 | 2023 | Senza |
| Shield Therapeutics INC | $17.19 | 2023 | Accrufer |
| Esperion Therapeutics, INC. | $15.17 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.85 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $5.00 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meagan Cherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.